Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Next Previous
Drug Profile

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Alternative Names: Aidixi; RC 48; RC 48-ADC; Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate - Yantai Rongchang Pharmaceutical

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yantai Rongchang Biological Engineering
  • Developer RemeGen; Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Registered Urogenital cancer
  • Preregistration HER2 positive breast cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gynaecological cancer; Malignant melanoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 12 May 2025 Efficacy and adverse events data from a phase-III clinical trials in Urogenital cancer released by RemeGen
  • 09 May 2025 RemeGen Co plans a phase III trial for Adenocarcinoma (Late stage disease, Metastatic disease, First line therapy, Combination therapy) in China (IV) in May 2025 (NCT06944496)
  • 15 Feb 2025 Updated efficacy data from a phase II trial in Bladder cancer released by RemeGen

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top